GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO

Watchlist Manager
GlaxoSmithKline Pharmaceuticals Ltd Logo
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Watchlist
Price: 2 264.6001 INR -0.8%
Market Cap: 383.6B INR
Have any thoughts about
GlaxoSmithKline Pharmaceuticals Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one GLAXO stock under the Base Case scenario is 1 882.3225 INR. Compared to the current market price of 2 264.6001 INR, GlaxoSmithKline Pharmaceuticals Ltd is Overvalued by 17%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GLAXO Relative Value
Base Case
1 882.3225 INR
Overvaluation 17%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

10.8
P/S
P/S
Price to Sales
10.8
vs History
14
vs Industry
12
Median 3Y
8.2
Median 5Y
8
Industry
2.5
Forward
9.9
More Details
56.8
P/E
P/E
Price to Earnings
56.8
vs History
44
vs Industry
4
Median 3Y
40.5
Median 5Y
52.3
Industry
21.8
Forward
43.3
More Details
39.5
P/OCF
P/OCF
Price to OCF
39.5
vs History
66
vs Industry
5
Median 3Y
47.5
Median 5Y
43.5
Industry
16.1
More Details
39.5
P/FCFE
P/FCFE
Price to FCFE
39.5
vs History
68
vs Industry
7
Median 3Y
49.8
Median 5Y
47.4
Industry
23.8
More Details
22.9
P/B
P/B
Price to Book Value
22.9
vs History
14
vs Industry
2
Median 3Y
17
Median 5Y
16.1
Industry
2.1
More Details
10.2
EV/S
EV/S
Enterprise Value to Sales
10.2
vs History
14
vs Industry
11
Median 3Y
7.4
Median 5Y
7.6
Industry
2.7
Forward
9.3
More Details
16.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
16.5
vs History
15
vs Industry
9
Median 3Y
13.2
Median 5Y
13.1
Industry
5.2
More Details
37.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
37.7
vs History
44
vs Industry
7
Median 3Y
32.1
Median 5Y
36.8
Industry
13.5
Forward
32
More Details
37.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
37.7
vs History
55
vs Industry
8
Median 3Y
34.4
Median 5Y
39.7
Industry
16.8
Forward
32.6
More Details
37.2
EV/OCF
EV/OCF
Enterprise Value to OCF
37.2
vs History
66
vs Industry
5
Median 3Y
45.2
Median 5Y
41.8
Industry
15.2
More Details
37.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
37.2
vs History
68
vs Industry
6
Median 3Y
45.5
Median 5Y
44.4
Industry
19.3
More Details
39.1
EV/IC
EV/IC
Enterprise Value to IC
39.1
vs History
11
vs Industry
2
Median 3Y
20.6
Median 5Y
18.5
Industry
1.9
More Details

Multiples Across Competitors

GLAXO Competitors Multiples
GlaxoSmithKline Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
383.6B INR 10.8 56.8 37.7 37.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
755.8B USD 18.5 90.3 48.5 54.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
351.1B USD 4 23.9 11.6 15.1
US
Merck & Co Inc
NYSE:MRK
251.8B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.5B USD 2.5 35.6 10.6 16
P/E Multiple
Earnings Growth P/E to Growth
IN
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Average P/E: 35.1
56.8
88%
0.6
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.3
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.9
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Average EV/EBITDA: 417.4
37.7
53%
0.7
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Average EV/EBIT: 1 813.9
37.7
57%
0.7
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.1
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15.1
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Summary
GLAXO intrinsic value, competitors valuation, and company profile.
DCF Valuation
GLAXO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GLAXO stock valuation using valuation multiples.
Wall Street Estimates
GLAXO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GLAXO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.